Condition: Triple Negative Breast Cancer · Sponsor: European Institute of Oncology
Triple-negative breast cancer (TNBC) is among the most aggressive and lethal types of breast cancer, and currently available therapies have an unsatisfactory impact on patients' survival. The primary aim of this clinical trial is to evaluate efficacy in terms of Overall Response Rate (ORR) of atezolizumab plus cyclophosphamide and vinorelbine in first line patients with unresectable locally advanced or metastatic TNBC patients, previously treated with anti-programmed cell death ligand-1 (PD-L1) or anti-programmed cell death-1 (PD-1) - containing regimens, in the neoadjuvant/adjuvant setting.
This description comes directly from the study's public registry record.
Elisabetta Munzone, MD · +39 0257489405 · elisabetta.munzone@ieo.it
Mara Negri · +39 0257489536 · mara.negri@ieo.it
Always discuss trial participation with your own doctor first.
| Fondazione IRCCS San Gerardo Dei Tintori | Monza, Monza, Italy | Recruiting |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Roma, Roma, Italy | Not Yet Recruiting |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Roma, Roma, Italy | Not Yet Recruiting |
| Azienda Sanitaria Locale Br | Brindisi, Italy | Not Yet Recruiting |
| European Institute of Oncology | Milan, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06690840